Dr. Anthony J. Olszanski
Claim this profileFox Chase Cancer Center
Studies Solid Tumors
Studies Tumors
16 reported clinical trials
25 drugs studied
Area of expertise
1Solid Tumors
Stage IV
Stage III
EGFR negative
2Tumors
Stage IV
Stage III
HPV negative
Affiliated Hospitals
Clinical Trials Anthony J. Olszanski is currently running
EU101
for Solid Cancers
Phase 1 (Dose Escalation) of this study will assess the safety, tolerability, dose-limiting toxicity (DLT), and will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of EU101 in participants with advanced solid tumors. Phase 2 (Dose Expansion) of the study will assess the antitumor effect of EU101 in two indications including colorectal cancer (CRC) and non-small cell lung cancer (NSCLC).
Recruiting1 award Phase 1 & 210 criteria
5-ALA Photodynamic Therapy
for Cancer
RDT aims to take advantage of the relatively safer toxicity profiles of both lower dose radiation therapy and systemic ALA to treat non-superficial lesions in a manner similar to photodynamic therapy. The doses of radiation administered in this study will be lower than those typically used to treat cancer. However, with administration of ALA, which has been shown to be selectively concentrated in neoplastic cells, it is reasonable to expect responses in the target lesion(s) with relative sparing of nearby normal structures. A similar therapy is currently being used in a single institution in China. Members of the Fox Chase Cancer Center have visited the Chinese medical site multiple times and have gained first-hand experience with this therapy. Based on thus-far unpublished data, this treatment appears to be both safe and well-tolerated. There have been marked responses seen in some of these patients, but this therapy has not yet been investigated in a more formalized clinical trial setting, nor has it been used on Western patients. Thus, while these findings are encouraging, much work is necessary to determine the efficacy and role of this intervention.
Recruiting2 awards Phase 122 criteria
More about Anthony J. Olszanski
Clinical Trial Related3 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Anthony J. Olszanski has experience with
- Nivolumab
- Pembrolizumab
- Dostarlimab
- GSK4428859A
- GSK4381562
- Gamitrinib
Breakdown of trials Anthony J. Olszanski has run
Solid Tumors
Melanoma
Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anthony J. Olszanski specialize in?
Anthony J. Olszanski focuses on Solid Tumors and Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Anthony J. Olszanski currently recruiting for clinical trials?
Yes, Anthony J. Olszanski is currently recruiting for 9 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Anthony J. Olszanski has studied deeply?
Yes, Anthony J. Olszanski has studied treatments such as Nivolumab, Pembrolizumab, Dostarlimab.
What is the best way to schedule an appointment with Anthony J. Olszanski?
Apply for one of the trials that Anthony J. Olszanski is conducting.
What is the office address of Anthony J. Olszanski?
The office of Anthony J. Olszanski is located at: Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 United States. This is the address for their practice at the Fox Chase Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.